Facebook Twitter Instagram
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Facebook Twitter Instagram
    Pharmacognosy Communications
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Pharmacognosy Communications
    retyeyutreu
    Original Article

    Metabolite profiling by UPLC-PDA-ESI/HDMS and antibacterial activity of Memecylon talbotianum Brandis

    wadmin2By wadmin2August 6, 2016Updated:August 11, 2021No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn WhatsApp Pinterest Email

    Tumkur Ramasetty Bharathi1, Shailasree Sekhar2, Kigga Kadappa Sampath Kumara1, Mudalabeedu Chandregowda Madhusudhan1 and Harishchandra Sripathy Prakash1*
    1Department of Studies in Biotechnology, University of Mysore, Manasagangotri, Mysuru–570 006, Karnataka, INDIA.
    2Institution of Excellence, Vijnana Bhavana, University of Mysore, Manasagangotri, Mysuru–570 006, Karnataka, INDIA.

    Pharmacognosy Communications,2016,6,4,225-231.
    DOI:10.5530/pc.2016.4.5
    Published: August 2016
    Type: Original Article

    ABSTRACT

    Introduction: UPLC based metabolite profiling was employed to evaluate the chemical constituents of Memecylon talbotianum Brandis extract and its antibacterial activity was studied in vitro. Methods: Methanol extracts of M. talbotianum was subjected to UPLC-PDA-ESI/HDMS metabolite profiling. The antibacterial activity was determined against human pathogens through disc diffusion, Minimum inhibitory concentration (MIC), Minimum biofilm inhibitory concentration (MBIC) test as visualized by Alamar blue and confocal laser scanning microscopy. Results: UPLC-PDA-ESI/HDMS analysis identified eighteen metabolites, synapoyl-hexose-formic acid, kaempferol 3-O-feruloylhexosyl rhamnoside, 6-C-arabinosyl-8-C-glucosylapigenin and isorhamnetin-3-O-glycoside-7-O-glycoside as the main constituents for the first time from this plant. A broad spectrum of antibacterial activity against to test human pathogens (MIC=54 mg/ mL; Gram-positive bacteria) causing lysis at 24 h incubation was reported, resulting in nearly a 4 log10 CFU / mL drop in cell viability at 1.6 X MIC (Gram-positive) for this extract. The extract at 2 fold MIC inhibited the bacterial biofilm formation and at 8 x MIC eradicated biofilms. However, a higher concentration of this extract was identified in this study for a similar effect on Gram-negative bacteria. Conclusion: The presence of these compounds could contribute to their in vitro inhibitory activities against pathogenic bacterial strains indicating its potential as medicinal agents in treatment and prevention of diseases of bacterial origin.

    Key words: UPLC-PDA-ESI/HDMS, Bioactives, Anti-bacterial activity, Biofilm, MIC.

    Download PDF
    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    About Journal
    About Journal

    Pharmacognosy Communications [Phcog Commn.] is a quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.
    Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
    Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.
    Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.

    © 2025 Pharmacognosy Communications. Maintained by Manuscript TechnoMedia LLP.

    Type above and press Enter to search. Press Esc to cancel.

    Scroll Up